MANIFEST-2, a global, phase 3, randomized, double-blind, active-control study of CPI-0610 and Ruxolitinib vs. placebo and Ruxolitinib in JAKi-treatment-naive Myelofibrosis (MF) patients

被引：0

作者：

Al-Ali, H. K. ^{[1
]}

Mascarenhas, J. ^{[2
]}

Harrison, C. ^{[3
]}

Luptakova, K. ^{[4
]}

Wang, J. ^{[4
]}

Colak, G. ^{[4
]}

Shao, J. ^{[4
]}

Bobba, S. ^{[4
]}

Trojer, P. ^{[4
]}

Humphrey, J. ^{[4
]}

Verstovsek, S. ^{[5
]}

机构：

[1] Univ Hosp Halle, Halle, Germany

[2] Icahn Sch Med Mt Sinai, Div Hematol Med Oncol, Tisch Canc Inst, New York, NY 10029 USA

[3] Guys & St Thomas Hosp, London, England

[4] Constellat Pharmaceut, Cambridge, MA USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ep298

引用

页码：164 / 164

页数：1

共 50 条

[1] Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
Mead, Adam
Mascarenhas, John
Gerds, Aaron
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Humphrey, Jeffrey
Verstovsek, Srdan
Harrison, Claire
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 101 - 102
[2] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Wang, Jing
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Humphrey, Jeffrey
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S363 - S363
[3] MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients
Mascarenhas, John
Harrison, Claire
Luptakova, Katarina
Christo, Jessica
Wang, Jing
Mertz, Jennifer A.
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Senderowicz, Adrian
Humphrey, Jeffrey S.
Verstovsek, Srdan
BLOOD, 2020, 136
[4] MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF CPI 0610 AND RUXOLITINIB VS. PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-TREATMENT-NAIVE MYELOFIBROSIS PATIENTS
Passamonti, F.
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Vannucchi, A.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Humphrey, J.
Verstovsek, S.
HAEMATOLOGICA, 2021, 106 (10) : 81 - 82
[5] Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naive Myelofibrosis Patients
Harrison, Claire N.
Patriarca, Andrea
Mascarenhas, John
Kremyanskaya, Marina
Hoffman, Ronald
Schiller, Gary J.
Leber, Brian
Devos, Timothy
Kabir, Sujan
Senderowicz, Adrian
Mertz, Jennifer
Trojer, Patrick
Shao, James
Gupta, Vikas
BLOOD, 2019, 134
[6] Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron T.
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna-Maria
Li, Qing
Brown, Barbara
Harrison, Claire N.
Mascarenhas, John
BLOOD, 2023, 142
[7] Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Harrison, Claire N.
Gupta, Vikas K.
Gerds, Aaron T.
Rampal, Raajit
Verstovsek, Srdan
Talpaz, Moshe
Kiladjian, Jean-Jacques
Mesa, Ruben
Kuykendall, Andrew T.
Vannucchi, Alessandro M.
Palandri, Francesca
Grosicki, Sebastian
Devos, Timothy
Jourdan, Eric
Wondergem, Marielle J.
Al-Ali, Haifa Kathrin
Buxhofer-Ausch, Veronika
Alvarez-Larran, Alberto
Patriarca, Andrea
Kremyanskaya, Marina
Mead, Adam J.
Akhani, Sanjay
Sheikine, Yuri
Colak, Gozde
Mascarenhas, John
FUTURE ONCOLOGY, 2022, 18 (27) : 2987 - 2997
[8] CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Devos, T.
Rampal, R.
Vannucchi, A.
Passamonti, F.
Mead, A.
Kremyanskaya, M.
Somervaille, T.
Wondergem, M.
Hoffman, R.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Verstovsek, S.
Gupta, V.
HAEMATOLOGICA, 2021, 106 (10) : 5 - 6
[9] CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: Update of MANIFEST phase 2 study
Platzbecker, U.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Devos, T.
Palandri, F.
Rampal, R.
Vannucchi, A.
Mead, A.
Kremyanskaya, M.
Somervaille, T.
Wondergem, M.
Hoffman, R.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Verstovsek, S.
Gupta, V
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 158 - 158
[10] CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study
Mead, Adam
Mascarenhas, John
Talpaz, Moshe
Patriarca, Andrea
Devos, Timothy
Palandri, Francesca
Passamonti, Francesco
Rampal, Raajit
Kremyanskaya, Marina
Scandura, Joseph
Somervaille, Tim
Wondergem, Marielle
Granacher, Nikki
Hoffman, Ronald
Gupta, Vikas
Luptakova, Katarina
Wang, Jing
Christo, Jessica
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Verstovsek, Srdan
Harrison, Claire
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 96 - 96

← 1 2 3 4 5 →